Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7(10):776–785. https://doi.org/10.1016/s2213-8587(19)30249-9

Article  CAS  PubMed  Google Scholar 

Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet (London, England) 400(10365):1788–1801. https://doi.org/10.1016/s0140-6736(22)02074-8

Article  CAS  Google Scholar 

American Diabetes Association Professional Practice Committee (2024) 9 Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2025. Diabetes care 48(1):181–206. https://doi.org/10.2337/dc25-S009

Article  Google Scholar 

Greiver M, Havard A, Bowles JK, Kalia S, Chen T, Aliarzadeh B, Moineddin R, Sherlock J, Hinton W, Sullivan F, O’Neill B, Pow C, Bhatt A, Rahman F, Meza-Torres B, Litchfield M, de Lusignan S (2021) Trends in diabetes medication use in Australia, Canada, England, and Scotland: a repeated cross-sectional analysis in primary care. Bri J Gen Pract : J Royal College Gen Pract 71(704):e209–e218. https://doi.org/10.3399/bjgp20X714089

Article  Google Scholar 

Lee CMY, Gibson AA, Humphries J, Nassar N, Colagiuri S (2023) Sex and age differences in the use of medications for diabetes and cardiovascular risk factors among 25,733 people with diabetes. PLoS ONE 18(10):e0287599. https://doi.org/10.1371/journal.pone.0287599

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morton JI, Ilomӓki J, Magliano DJ, Shaw JE (2021) The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study. Diabetologia 64(2):349–360. https://doi.org/10.1007/s00125-020-05304-3

Article  CAS  PubMed  Google Scholar 

Ofori-Asenso R, Liew D, Lalic S, Mazidi M, Magliano DJ, Ademi Z, Bell JS, Ilomaki J (2019) Adherence, persistence, and switching among people prescribed sodium glucose co-transporter 2 inhibitors: a nationwide retrospective cohort study. Adv Ther 36(11):3265–3278. https://doi.org/10.1007/s12325-019-01077-3

Article  CAS  PubMed  Google Scholar 

de Oliveira CJ, Lin J, Milder TY, Greenfield JR, Day RO, Stocker SL, Neuen BL, Havard A, Pearson SA, Falster MO (2024) Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales. Diabetes Obes Metab, Australia. https://doi.org/10.1111/dom.15597

Book  Google Scholar 

Mahtta D, Ramsey DJ, Lee MT, Chen L, Al Rifai M, Akeroyd JM, Vaughan EM, Matheny ME, Santo K, Navaneethan SD, Lavie CJ, Birnbaum Y, Ballantyne CM, Petersen LA, Virani SS (2022) Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and Type 2 diabetes: insights from the Department of Veterans Affairs. Diabetes Care 45(2):372–380. https://doi.org/10.2337/dc21-1815

Article  CAS  PubMed  PubMed Central  Google Scholar 

Warren JR, Falster MO, Fox D, Jorm L (2013) Factors influencing adherence in long-term use of statins. Pharmacoepidemiol Drug Saf 22(12):1298–1307. https://doi.org/10.1002/pds.3526

Article  CAS  PubMed  Google Scholar 

Zhao Z, Zhao F, Zhang Y, Hu X, Li J, Tian C, Jin P, Liu D (2023) Risk factors of dapagliflozin-associated diabetic ketosis/ketoacidosis in patients with type 2 diabetes mellitus: a matched case-control study. Diabetes Res Clin Pract 196:110236. https://doi.org/10.1016/j.diabres.2023.110236

Article  CAS  PubMed  Google Scholar 

Milder TY, Stocker SL, Baysari M, Day RO, Greenfield JR (2021) Prescribing of SGLT2 inhibitors in primary care: a qualitative study of General Practitioners and Endocrinologists. Diabetes Res Clin Pract 180:109036. https://doi.org/10.1016/j.diabres.2021.109036

Article  CAS  PubMed  Google Scholar 

Bleicher K, Summerhayes R, Baynes S, Swarbrick M, Navin Cristina T, Luc H, Dawson G, Cowle A, Dolja-Gore X, McNamara M (2022) Cohort profile update: the 45 and Up Study. Int J Epidemiol 52(1):e92–e101. https://doi.org/10.1093/ije/dyac104

Article  PubMed Central  Google Scholar 

The Sax Institute’s 45 and Up Study. 5 Dec 2022. Cited 13 May 2025. Available from: www.saxinstitute.org.au/solutions/45-and-up-study/

Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ, Segrave A, Pearson SA (2015) The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Res Notes 8:634. https://doi.org/10.1186/s13104-015-1616-8

Article  PubMed  PubMed Central  Google Scholar 

NPS MedicineWise (2015) SGLT2 inhibitor listings: indications and combinations. Accessed 1 Jul 2022. Available from: https://www.nps.org.au/radar/articles/sglt2-inhibitor-listings-indications-and-combinations

NPS MedicineWise (2010) Exenatide (Byetta) for type 2 diabetes mellitus. Accessed 1 Jul 2022. Available from: https://www.nps.org.au/radar/articles/exenatide-byetta-for-type-2-diabetes-mellitus

Comino EJ, Tran DT, Haas M, Flack J, Jalaludin B, Jorm L, Harris MF (2013) Validating self-report of diabetes use by participants in the 45 and Up Study: a record linkage study. BMC Health Serv Res 13:481. https://doi.org/10.1186/1472-6963-13-481

Article  PubMed  PubMed Central  Google Scholar 

Sax Institute (2021) The 45 and Up Study Wave 3 Data Book Second Follow-Up, 2018–2020. Cited 13 May 2025. Available from: https://www.saxinstitute.org.au/wp-content/uploads/W3-databook-May2021.pdf

Australian Insitute of Health and Welfare (2023) The Active Australia Survey: a guide and manual for implementation, analysis and reporting. Accessed 1 Jul 2022. Available from: https://www.aihw.gov.au/reports/physical-activity/active-australia-survey/summary

Pratt NL, Kerr M, Barratt JD, Kemp-Casey A, KalischEllett LM, Ramsay E, Roughead EE (2018) The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System. BMJ Open 8(4):e021122. https://doi.org/10.1136/bmjopen-2017-021122

Article  PubMed  PubMed Central  Google Scholar 

Liu Z, Moorin R, Worthington J, Tofler G, Bartlett M, Khan R, Zuo Y (2016) Using large-scale linkage data to evaluate the effectiveness of a National Educational Program on antithrombotic prescribing and associated stroke prevention in primary care. J Am Heart Assoc 5(10) https://doi.org/10.1161/jaha.116.003729

Lin J, Pearson S-A, Greenfield JR, Park KH, Havard A, Brieger D, Day RO, Falster MO, de Oliveira CJ (2023) Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022). Eur J Clin Pharmacol 79(9):1239–1248. https://doi.org/10.1007/s00228-023-03539-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morton JI, Ilomӓki J, Magliano DJ, Shaw JE (2022) Persistent disparities in diabetes medication receipt by socio-economic disadvantage in Australia. Diabet Med : J Bri Diabet Assoc 39(9):e14898. https://doi.org/10.1111/dme.14898

Article  Google Scholar 

Arnold SV, Tang F, Cooper A, Chen H, Gomes MB, Rathmann W, Shimomura I, Vora J, Watada H, Khunti K, Kosiborod M (2022) Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Result Dis BMC Endocrine Disord 22(1):111. https://doi.org/10.1186/s12902-022-01026-2

Article  CAS  Google Scholar 

Khera R, Dhingra LS, Aminorroaya A, Li K, Zhou JJ, Arshad F, Blacketer C, Bowring MG, Bu F, Cook M, Dorr DA, Duarte-Salles T, DuVall SL, Falconer T, French TE, Hanchrow EE, Horban S, Lau WC, Li J, Liu Y, Lu Y, Man KK, Matheny ME, Mathioudakis N, McLemore MF, Minty E, Morales DR, Nagy P, Nishimura A, Ostropolets A, Pistillo A, Posada JD, Pratt N, Reyes C, Ross JS, Seager S, Shah N, Simon K, Wan EY, Yang J, Yin C, You SC, Schuemie MJ, Ryan PB, Hripcsak G, Krumholz H, Suchard MA (2023) Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM. BMJ Medicine 2(1):e000651. https://doi.org/10.1136/bmjmed-2023-000651

Article  PubMed  PubMed Central  Google Scholar 

Lim CE, Pasternak B, Eliasson B, Danaei G, Ueda P (2023) Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol 30(8):634–643. https://doi.org/10.1093/eurjpc/zwac315

Article  PubMed  Google Scholar 

Australian Diabetes Society (2020) Australian type 2 diabetes glycaemic management algorithm 2020. Cited 13 May 2025. Available from: https://www.diabetessociety.com.au/20200908%20T2D%20Management%20Algorithm%2003092020.pdf

Australian National Diabetes Audit Annual Report 2022. (2023) Monash University, School of Public Health and Preventive Medicine. Report No 15, 91 pages

Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, Hare MJL, Calder GL, Epa DS, George EM, Giri R, Kotowicz MA, Kyi M, Lafontaine N, MacIsaac RJ, Nolan BJ, O’Neal DN, Renouf D, Varadarajan S, Wong J, Xu S, Bach LA (2019) SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab 104(8):3077–3087. https://doi.org/10.1210/jc.2019-00139

Article  PubMed  Google Scholar 

Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H (2025) Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiat 82(1):94–98. https://doi.org/10.1001/jamapsychiatry.2024.3599

Article  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, Association obotAD, (2022) 9 Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care 46(1):140–157. https://doi.org/10.2337/dc23-S009

Article  Google Scholar 

Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, Handelsman Y, Verma S, Anker SD, McMurray JJV, Kosiborod MN, Butler J (2020) Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization. Circulation 142(12):1205–1218. https: